A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients
Phase of Trial: Phase I/II
Latest Information Update: 04 Mar 2017
At a glance
- Drugs Nintedanib (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 08 Dec 2016 Status changed from active, no longer recruiting to completed.
- 03 Dec 2016 This trial has been completed in Germany (end date: 12 Oct 2016).
- 05 Nov 2016 This trial has been completed Austria and Hungary (end date: 2016-10-03), according to European Clinical Trials Database record.